logo

Biota Pharmaceuticals Inc. (AVIR)



Trade AVIR now with
  Date
  Headline
1/11/2018 7:55:02 PM Aviragen Board Recommends Tht Stockholders Vote FOR Proposed Merger With Vaxart
11/29/2017 7:07:42 AM Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial Of Teslexivir For Condyloma
10/30/2017 7:07:18 AM Aviragen Therapeutics, Vaxart Enter Definitive Merger Agreement
8/31/2017 4:03:43 PM Aviragen Therapeutics Q1 Loss/share $0.15 Vs. Loss $0.18 Year Ago
5/4/2017 7:14:58 AM Aviragen Therapeutics Q1 Net Loss $4.4 Mln Or $0.11/shr Vs Net Loss $5.2 Mln Or $0.14/shr Last Year
4/4/2017 6:08:31 AM Aviragen Therapeutics Announces Review Of Strategic Alternatives And Provides Corporate Update
1/9/2017 6:04:17 AM Immunomedics Appoints Four New Independent Directors; Announces Chairman And CEO Succession Plans
7/12/2016 7:03:12 AM Aviragen Therapeutics Resumes Enrollment In Its Phase 2a Challenge Study Of BTA585
12/22/2015 8:35:31 AM FBR Capital Markets Starts Biota Pharmaceuticals Inc. (BOTA) At Outperform With $6 Price Target